pembrolizumab,ipilimumab,nivolumab
merck,bms
['keytruda', 'opdivo', 'melanoma', 'yervoy']
today, #intervenn is making history with dawn io melanoma. now, you can
assess your patient's likelihood of benefit before starting #immunotherapy
(validated for opdivo , yervoy &amp; keytruda ). #dawn #asco2022 #melanoma #liquidbiopsy #glycoproteomics 
InterVenn Biosciences' Official Twitter | InterVenn is a patient-driven, employee-first biotechnology organization researching on diseases in a radical manner.